Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
+$0.15 today
- Market cap
- $1.54B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
Volume 2.79M
Average 1.74M
NRIX Total Non-current Assets
All assets not expected to be converted to cash within one year.
Nurix Therapeutics, Inc.NASDAQ: NRIX
Total Non-current Assets · Q3 FY2026 · quarter ended Aug 2026
Total non-current assets rises 11.9% from a year ago
Total non-current assets stood at $91.61M at the end of Q3 FY2026, up 11.9% from a year earlier and up 15.9% from the prior quarter. Over 3 fiscal years it compounded at -6.1% a year.
Context
- Total non-current assets amounted to 7.7% of total assets at the end of Q3 FY2026, down 8.0 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +11.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 81.32M USD
- Year-over-year change
- +62.8%
- 4-year CAGR
- -16.3%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-11-30 | 81.32M | +62.8% |
| FY2024 | 2024-11-30 | 49.96M | -16.9% |
| FY2023 | 2023-11-30 | 60.1M | -38.9% |
| FY2022 | 2022-11-30 | 98.31M | -40.7% |
| FY2021 | 2021-11-30 | 165.65M | — |
Total Non-current Assets vs competitors
How NRIX compares with its peers on the latest reported figures
- NRIX's Aug 2026 total non-current assets of $91.61M is the 4th highest of the 8 companies compared; the peer median is $83.49M.
- Its year-over-year change of +11.9% is the 5th highest of 8, against a peer median of +16.5%.
- Total non-current assets amounts to 7.7% of total assets for NRIX, versus a peer median of 6.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $902M | +124.0% | +68.0% | 54.8% | |
| Jun 2026 | $294.93M | +16.5% | +22.6% | 6.8% | |
| Mar 2026 | $270.58M | +820.1% | +146.0% | 53.6% | |
| Aug 2026 | $91.61M | +11.9% | -6.1% | 7.7% | |
| Mar 2026 | $83.49M | -4.0% | -11.0% | 25.4% | |
| Sep 2026 | $40.8M | -12.0% | -9.8% | 3.9% | |
| Mar 2026 | $28.77M | +47.0% | +44.3% | 4.4% | |
| Mar 2026 | $1.49M | -98.4% | -39.8% | 0.3% | |
| Peer median (excluding NRIX) | $83.49M | +16.5% | +22.6% | 6.8% | |
Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Nov 2021 | FY2022 Nov 2022 | FY2023 Nov 2023 | FY2024 Nov 2024 | FY2025 Nov 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 80.51M | 64.47M | 54.63M | 110M | 246.96M |
| Short-term Investments | 215.21M | 244.67M | 233.28M | 499.59M | 345.98M |
| Net Receivables | 6.2M | 1.1M | 800K | 1.5M | 0 |
| Inventory | 0 | (1.1M) | 0 | 0 | 0 |
| Other Current Assets | 900K | 9.31M | 6.8M | 8.3M | 13.88M |
| Total Current Assets | 311.12M | 318.45M | 295.5M | 619.39M | 606.82M |
| Property, Plant & Equipment (Net) | 25.35M | 29.51M | 47.95M | 45.9M | 73.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 137.48M | 63.88M | 7.42M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.12M | 4.92M | 4.72M | 4.06M | 8.31M |
| Total Non-current Assets | 165.65M | 98.31M | 60.1M | 49.96M | 81.32M |
| Total Assets | 476.77M | 416.76M | 355.6M | 669.34M | 688.14M |
| Account Payables | 6.65M | 5.06M | 6.4M | 11.48M | 11.22M |
| Short-term Debt | 3.85M | 5.53M | 7.49M | 0 | 0 |
| Tax Payables | 75K | 85K | 30K | 1.24M | 0 |
| Deferred Revenue | 41.21M | 37.63M | 48.1M | 38.36M | 17.58M |
| Other Current Liabilities | 5.67M | 9.14M | 751K | 18.91M | 23.64M |
| Total Current Liabilities | 66.26M | 70.66M | 86.96M | 95.85M | 86.47M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 59.02M | 35.97M | 45.02M | 26.21M | 10.01M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 68.21M | 42.41M | 68.15M | 46.5M | 62.92M |
| Total Liabilities | 134.47M | 113.06M | 155.11M | 142.35M | 149.39M |
| Common Stock | 45K | 47K | 49K | 76K | 102K |
| Retained Earnings | (220.89M) | (401.25M) | (545.2M) | (738.77M) | (1B) |
| Accumulated OCI | (608K) | (4.32M) | (655K) | 150K | 105K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 342.3M | 303.7M | 200.49M | 526.99M | 538.75M |
| Total Debt | 13.04M | 11.96M | 30.61M | 28.3M | 55.73M |
| Net Debt | (67.47M) | (52.51M) | (24.01M) | (81.69M) | (191.23M) |
Nurix Therapeutics, Inc.
NASDAQ:NRIX
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.